News Archives - Aurobindo Pharma USA
WEBFeb 9, 2024 · East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Fluphenazine Hydrochloride Tablets 1mg, 2.5mg, 5mg, and 10mg.
Aurobindo Pharma faces setback as US FDA issues 10 …
WEB2 days ago · Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) has completed its inspection at Unit II of Apitoria Pharma Private Limited, a wholly-owned subsidiary of Aurobindo, located in Telangana.
Aurobindo Pharma Outperforms Expectations with Strong Q4, …
WEBMay 27, 2024 · Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA...
Aurobindo, major generic drug maker, will close a key U.S ... - STAT
WEBMar 22, 2022 · A urobindo Pharma, which is based in India and is one of the largest global producers of generic medicines, is closing its U.S. manufacturing facility in New Jersey next month, according to a...
FDA classifies Aurobindo plant as needing 'voluntary' action
WEBDec 20, 2023 · The FDA has issued its final inspection report for an Aurobindo plant in India after a September inspection and a subsequent Form 483. The agency classified the plant as needing "voluntary"...
Aurobindo cuts production at a key facility amid shortage …
WEBFeb 9, 2024 · A urobindo, which is one of the largest generic drug makers, has halted some production at a key facility in India after U.S. inspectors found manufacturing problems, the latest such episode to...
India's Aurobindo Pharma posts jump in profit on strong overseas …
WEBNov 9, 2023 · India's Aurobindo Pharma Ltd reported a better-than-expected 84.9% rise in second-quarter profit on Thursday, driven by strong sales in core markets Europe and the United States amid stablising...
Home | Aurobindo Pharma USA
WEBNews. Product News. February 09, 2024 | Aurobindo Receives FDA Approval for Deflazacort Tablets 6mg, 18mg, 30mg, & 36mg ... Read more. Industry News. December 24, 2020 | Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to Develop and Commercialize COVID-19 Vaccine UB-612 for India and …
Aurobindo Pharma Q2 Results: Net profit soars 84% to Rs 752 …
WEBNov 9, 2023 · Aurobindo Pharma on Thursday reported 84% year-on-year (YoY) rise in net profit to Rs 752 crore in the second quarter ended September 2023, led by strong sales from the US market. The company posted net profit of Rs 409 crore in the corresponding quarter of the previous year.
Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to …
WEBDec 24, 2020 · Aurobindo Pharma Limited and COVAXX, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children’s Fund (UNICEF) agency.